Which Pharma Stocks Face the Highest Risk from US Tariffs?
The recent US tariff announcements under President Donald Trump have rattled Indian pharmaceutical companies, especially those heavily dependent on American revenues. But not all pharma players face the same level of threat. The degree of exposure largely depends on whether a company has US-based manufacturing facilities, the type of products it sells, and its overall portfolio diversification. Let us break down the risk levels for Indian pharma majors.
About the Tariff Shock for Indian Pharma
The United States is the largest export market for Indian drug manufacturers, contributing nearly 40% of India’s pharma exports. With tariffs now targeting branded and patented drugs, companies with a significant share of US sales but no local manufacturing footprint are the most vulnerable. Meanwhile, firms with US plants or specialty product lines such as injectables, biosimilars, and respiratory drugs may find partial or complete shelter from the new tariff storm.
High-Risk Pharma Stocks
Gland Pharma stands out as the most vulnerable with over 50% of its revenue from the US and no local plants. Its injectables portfolio, already under pricing stress, will not receive exemptions. Investors should closely monitor how this pressure affects margins and growth.
Medium-Risk Pharma Stocks
Companies like Dr. Reddy’s, with around 43–46% of revenue from the US, fall into this category. While it has some US presence, branded generics may still attract tariffs if not made locally. Partial exemptions reduce but do not eliminate the risk.
Low-Risk Pharma Stocks
Several companies appear better positioned to weather the tariff storm:
- Syngene – With a Baltimore biologics site, most of its 69% US revenue is protected.
- Biocon – Its NJ site supports biosimilars, shielding branded products like insulin.
- Zydus Lifesciences – Multiple US CDMO sites help minimize tariff exposure.
- Glenmark – Its Monroe, NC site ensures injectables and solids remain shielded.
- Aurobindo Pharma – NJ facilities safeguard its broad portfolio.
- Piramal Pharma – US CDMO assets in Kentucky & Michigan reduce risk significantly.
- Lupin – With US sites in Florida and New Jersey, respiratory & biotech assets stay protected.
- Sun Pharma – Specialty products exempt via its US presence.
- Cipla – Inhalers and oral solids shielded by multiple US facilities.
- Alkem – Through Enzene Biosciences, biosimilars are protected.
For those tracking near-term momentum in markets, here’s a quick look 👉 Nifty Tip | BankNifty Tip.
Key Takeaways for Investors
The tariff shock is not uniform across the pharma sector. While Gland Pharma faces the steepest risks due to zero US manufacturing, companies like Biocon, Syngene, and Lupin benefit from their American footprint. Product categories also matter: biosimilars and specialty drugs are more shielded than pure-play generics. Investors should carefully evaluate each company’s US exposure before making allocation decisions.
Stay ahead of evolving market risks with in-depth insights available at Indian-Share-Tips.com, which is a SEBI Registered Advisory Services.
SEBI Disclaimer: The information provided in this post is for informational purposes only and should not be construed as investment advice. Readers must perform their own due diligence and consult a registered investment advisor before making any investment decisions. The views expressed are general in nature and may not suit individual investment objectives or financial situations.
